HOME >> BIOLOGY >> NEWS
Evidence links protein damage to Parkinson's

Philadelphia -- New evidence links oxidative damage in a protein found in nerve cells to the development of degenerative diseases of the nervous system, such as Parkinson's and Alzheimer's. The first study to provide this evidence, conducted by University of Pennsylvania researchers, will be published in the November 3 issue of Science.

"The protein, called alpha-synuclein, is one of the building blocks of the brain lesions characteristic in patients with neurodegenerative diseases," says Dr. Virginia Lee, who is the John H. Ware III Professor in Alzheimer Research and co-director of the Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. Oxidative damage, she explains, normally occurs when the body's cells are overwhelmed by molecules that have changed because they have combined with nitrogen (nitration) or oxygen (oxidation).

Both types of oxidants damage lipids, nucleic acids, proteins, and other cellular components much like oxidation causes rust damage to metal in cars and buildings. This damage has been implicated in causing neurodegenerative disorders.

"We found that alpha-synuclein itself is a target of oxidative stress, specifically nitration, within these lesions, " says Lee. "This is the first time anybody has identified nitration on a specific protein."

Neurodegenerative diseases -- including Parkinson's, Alzheimer's, diffuse Lewy body disease, and multiple system atrophy -- are collectively called synucleinopathies. Most commonly they become symptomatic due to a deficiency of a specific neurotransmitter -- in the case of Parkinson's it is dopamine. When the neurons that produce these chemicals die or become impaired, which occurs with oxidation, the eventual results are tremors and sometimes dementia.

"Alpha-synuclein is found at the synapses of nerve cells," explains Lee. Earlier studies showed that two mutati
'"/>

Contact: Ellen O'Brien
ellen.obrien@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
1-Nov-2000


Page: 1 2

Related biology news :

1. Evidence builds for potential new cancer drug target
2. Evidence for sympatric speciation by host shift in the sea
3. Evidence for the impact of climate change on deep-sea biodiversity
4. Evidence for fat hormone target in brain
5. Evidence of nanobacterial-like structures found in human calcified arteries and cardiac valves
6. Evidence shows the heart has stem cells able to regenerate muscle tissue lost to disease, wear
7. Evidence for orangutan culture
8. Evidence suggests that standard smallpox vaccine offers long-term immunity
9. Evidence that adults stem cells differentiate like embryonic stem cells published in Nature
10. When Shewanella meets goethite: Evidence found of recognition between animate and inanimate objects
11. Evidence suggests food preservatives may help prevent cavities

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: